Sensei acquires key technology to treat endometrial cancer, raises $200M

Boston-based Sensei Biotherapeutics has finalized its acquisition of Faeth Therapeutics and secured a $200 million private placement to help it accelerate clinical programs targeting cancers that disproportionately affect women. The acquisition brings Faeth’s lead asset, PIKTOR, a proprietary oral drug that has shown promise in treating endometrial cancer in clinical trials. The company will use the proceeds to advance PIKTOR through clinical milestones, adding that PIKTOR has also proven to be effective in treating advanced stage breast cancer. The American Cancer Association says more than 68,000 cases of endometrial cancer will be diagnosed this year, with more than 14,000 deaths.